Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance
Emily L. Hopewell, … , Dung-Tsa Chen, Amer A. Beg
Emily L. Hopewell, … , Dung-Tsa Chen, Amer A. Beg
Published May 1, 2013
Citation Information: J Clin Invest. 2013;123(6):2509-2522. https://doi.org/10.1172/JCI67250.
View: Text | PDF
Research Article Oncology

Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance

  • Text
  • PDF
Abstract

NF-κB is constitutively activated in many cancer types and is a potential key mediator of tumor-associated inflammation, tumor growth, and metastasis. We investigated the role of cancer cell NF-κB activity in T cell–mediated antitumor responses. In tumors rendered immunogenic by model antigen expression or following administration of antitumor vaccines, we found that high NF-κB activity leads to tumor rejection and/or growth suppression in mice. Using a global RNA expression microarray, we demonstrated that NF-κB enhanced expression of several T cell chemokines, including Ccl2, and decreased CCL2 expression was associated with enhanced tumor growth in a mouse lung cancer model. To investigate NF-κB function in human lung tumors, we identified a gene expression signature in human lung adenocarcinoma cell lines that was associated with NF-κB activity level. In patient tumor samples, overall lung tumor NF-κB activity was strongly associated with T cell infiltration but not with cancer cell proliferation. These results therefore indicate that NF-κB activity mediates immune surveillance and promotes antitumor T cell responses in both murine and human lung cancer.

Authors

Emily L. Hopewell, Weipeng Zhao, William J. Fulp, Crystina C. Bronk, Alexis S. Lopez, Michael Massengill, Scott Antonia, Esteban Celis, Eric B. Haura, Steven A. Enkemann, Dung-Tsa Chen, Amer A. Beg

×

Figure 3

Impact of T cell chemokines on tumor rejection.

Options: View larger image (or click on image) Download as PowerPoint
Impact of T cell chemokines on tumor rejection.
(A) IFN-γ production by ...
(A) IFN-γ production by OT-1 CD8 T cells. ELISpot of OT-I T cells cultured with LLC parental, LLC-OVA, LLC-OVA-MiG, or LLC-OVA-IKK tumor cells (1 × 105 LLC cells per well; 1 × 105 T cells per well). Samples were run in triplicate (mean ± SEM). (B) C57BL/6 mice received s.c. LLC-OVA-MiG or LLC-OVA-IKK. Tumors were excised at day 9, and CD8 expression was determined using IHC. Typical results from 1 mouse per group out of 4 mice is shown. Scale bars: 150 μm (left); 30 μm (right). (C) Affymetrix probe set signal intensity of indicated chemokines in LLC-OVA-IKK compared with that in LLC-OVA-MiG. Genes identified in 2 separate microarray experiments are shown (mean ± SEM). (D) RT-PCR showing CCL2 and CCL5 expression in LLC parental, LLC transduced with OVA, and LLC transduced with OVA and MiG or OVA and IKK. Samples were run in triplicate (average ± SEM). (E) Lentivirus-expressing scrambled shRNA (Lenti-Cont) and LLC-OVA-IKK Ccl2 shRNA (Lenti-Ccl2) cells were injected s.c. in C57BL/6 mice, and tumor growth was monitored. Each line represents tumor growth in a single mouse. All results are representative of at least 2 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts